Shares of Regulus Therapeutics (NASDAQ:RGLS) spiked on Thursday after the microRNA-focused drug developer announced additional topline data from a Phase 1b trial for its lead asset, farabursen ...

Regulus (RGLS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

Investing.com -- Shares of Regulus Therapeutics (NASDAQ:RGLS) soared 23.3% today following the announcement of successful results from its Phase 1b multiple ascending dose (MAD) clinical trial of ...

Also Read: Why Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday? The full cohort of 26 patients demonstrated a similar mechanistic response based on urinary PC1 and ...

In this article, we are going to take a look at where Regulus Therapeutics Inc. (NASDAQ:RGLS) stands against other best short-term stocks with a buying opportunity for investors. Thrilling highs ...

This project has not set up a SECURITY.md file yet.